UY34065A - Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra malignidades sólidas - Google Patents
Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra malignidades sólidasInfo
- Publication number
- UY34065A UY34065A UY0001034065A UY34065A UY34065A UY 34065 A UY34065 A UY 34065A UY 0001034065 A UY0001034065 A UY 0001034065A UY 34065 A UY34065 A UY 34065A UY 34065 A UY34065 A UY 34065A
- Authority
- UY
- Uruguay
- Prior art keywords
- volasertib
- malignities
- pharmaceutical composition
- composition containing
- against solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere al uso de Volasertib o una sal o su hidrato para tratar pacientes que sufren de malignidades sólidas que incluyen malignidades sólidas avanzadas o metastásicas que comprenden una administración de alta frecuencia de Volasertib de acuerdo con un programa de dosificación específico .
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11165958 | 2011-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34065A true UY34065A (es) | 2012-11-30 |
Family
ID=46046245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034065A UY34065A (es) | 2011-05-13 | 2012-05-11 | Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra malignidades sólidas |
Country Status (15)
Country | Link |
---|---|
US (3) | US20130131069A1 (es) |
EP (1) | EP2707001B1 (es) |
JP (1) | JP2014513144A (es) |
KR (1) | KR20140025460A (es) |
CN (1) | CN103533941A (es) |
AR (1) | AR086390A1 (es) |
AU (1) | AU2012257833A1 (es) |
BR (1) | BR112013029182A2 (es) |
CA (1) | CA2835717A1 (es) |
CL (1) | CL2013003198A1 (es) |
EA (1) | EA201301265A1 (es) |
IL (1) | IL228882A0 (es) |
MX (1) | MX2013013059A (es) |
UY (1) | UY34065A (es) |
WO (1) | WO2012156283A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
US20150031699A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0797333A (ja) * | 1993-08-04 | 1995-04-11 | Takeda Chem Ind Ltd | 超分子構造型集合体 |
CN101200457A (zh) | 2003-02-26 | 2008-06-18 | 贝林格尔英格海姆法玛两合公司 | 二氢蝶啶酮、其制法及作为药物制剂的用途 |
US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
-
2012
- 2012-05-09 US US13/467,142 patent/US20130131069A1/en not_active Abandoned
- 2012-05-11 JP JP2014509744A patent/JP2014513144A/ja active Pending
- 2012-05-11 MX MX2013013059A patent/MX2013013059A/es not_active Application Discontinuation
- 2012-05-11 UY UY0001034065A patent/UY34065A/es unknown
- 2012-05-11 KR KR1020137030104A patent/KR20140025460A/ko not_active Application Discontinuation
- 2012-05-11 WO PCT/EP2012/058704 patent/WO2012156283A1/en active Application Filing
- 2012-05-11 BR BR112013029182A patent/BR112013029182A2/pt not_active IP Right Cessation
- 2012-05-11 EP EP12719756.4A patent/EP2707001B1/en active Active
- 2012-05-11 AR ARP120101699A patent/AR086390A1/es unknown
- 2012-05-11 CN CN201280023792.3A patent/CN103533941A/zh active Pending
- 2012-05-11 CA CA2835717A patent/CA2835717A1/en not_active Abandoned
- 2012-05-11 AU AU2012257833A patent/AU2012257833A1/en not_active Abandoned
- 2012-05-11 EA EA201301265A patent/EA201301265A1/ru unknown
-
2013
- 2013-10-15 IL IL228882A patent/IL228882A0/en unknown
- 2013-11-07 CL CL2013003198A patent/CL2013003198A1/es unknown
-
2016
- 2016-06-22 US US15/189,146 patent/US20160303131A1/en not_active Abandoned
-
2019
- 2019-06-13 US US16/440,053 patent/US20190290652A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130131069A1 (en) | 2013-05-23 |
AU2012257833A1 (en) | 2013-10-31 |
CN103533941A (zh) | 2014-01-22 |
IL228882A0 (en) | 2013-12-31 |
KR20140025460A (ko) | 2014-03-04 |
WO2012156283A1 (en) | 2012-11-22 |
BR112013029182A2 (pt) | 2017-01-31 |
US20190290652A1 (en) | 2019-09-26 |
EP2707001A1 (en) | 2014-03-19 |
CA2835717A1 (en) | 2012-11-22 |
MX2013013059A (es) | 2014-02-20 |
CL2013003198A1 (es) | 2014-06-20 |
EP2707001B1 (en) | 2016-12-21 |
US20160303131A1 (en) | 2016-10-20 |
AR086390A1 (es) | 2013-12-11 |
JP2014513144A (ja) | 2014-05-29 |
EA201301265A1 (ru) | 2014-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34065A (es) | Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra malignidades sólidas | |
MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
PH12016502132A1 (en) | Aryl-or heteroaryl-substituted benzene compounds | |
BR112015032432A2 (pt) | Conjugado de oligonucleotídeo antisense, oligômero, composição farmacêutica, uso de um oligômero ou conjugado de oligonucleotídeo antisense ou composição farmacêutica, método de tratamento da hipercolesterolemia ou de distúrbios relacionados e método in vivo ou in vitro | |
UY34076A (es) | Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra tumores sólidos avanzados | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
PH12015500730A1 (en) | Inhibitors of histone demethylases | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
IN2014MN00948A (es) | ||
AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
PH12017501688A1 (en) | Intranasal benzodiazepine pharmaceutical compositions | |
GT201600027A (es) | Inhibidores de rorc2 y sus métodos de uso | |
MY175764A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
BR112014004577A2 (pt) | inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos | |
MY171048A (en) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions | |
PE20151526A1 (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod | |
PH12017500923A1 (en) | New dosage and use of a a2a antagonist | |
BR112013024196A2 (pt) | complexos de gálio, composições farmacêuticas e métodos de uso | |
UA115307C2 (uk) | Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри | |
CL2012002358A1 (es) | Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12. | |
EA201590732A1 (ru) | Диспергируемая таблетка | |
PH12015501179A1 (en) | Fixed dose pharmaceutical composition comprising mometasone and azelastine | |
AR089136A1 (es) | Variantes de osteopontina para usar en la supresion o prevencion del crecimiento tumoral y composiciones que las contienen | |
AR116040A2 (es) | Sal tosilato para-toluensulfonato de 4-(6-cloro-3-metil-4,10-dihidro-3h-2,3,4,9-tetraazabenzo[f]azulen-9-carbonil)-2-fluoro-bencilamida del ácido ciclopropancarboxílico |